Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametinib plus intrathecal pemetrexed for meningeal metastases after first-line EGFR TKI failure
ChiCTR2000041527Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib and pemetrexed in Non-small cell lung cancer adenocarcinoma (NSCLC) and Carcinomatous Meningitis (CM), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: Overall survival. Started Dec 2020; status: recruiting.
02
Drugs
imatinibpemetrexed
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2000041527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041527.